The present disclosure is directed to the field of infection treatment and, in particular, to an infused undergarment that can be employed to increase colonization of Lactobacillus in women with vaginal infections.
Vaginitis, infection or inflammation of the vagina or vulva, is a common issue recognized in gynecology offices all over the country. Whether originating from bacterial or yeast overgrowth, patients complain of discharge, itching, burning, or embarrassing odor. In many cases women report recurrent infections with no recourse for effective long term treatment or prevention. Currently, the best clinical advice is for these women to wear a cotton undergarment, send a culture, and a prescription for antibiotic or antifungal is given. However, this course of action is treating symptoms and does not resolve the underlying cause. When patients are presented with symptoms, cultures are sent to a laboratory for both pathologic organisms and normal flora bacteria. Anecdotal evidence shows a strong pattern can be seen in those with recurring yeast or bacterial infections, namely these women lacked colonization with Lactobacillus.
At present, there are no formulations of probiotics that are designed to colonize the vagina directly. There are researchers attempting to develop a vaginal tablet; however, the use of a tablet will require FDA approval, a prescription from a physician to obtain it, and the task of the patient inserting themselves correctly.
It is widely accepted that the presence of Lactobacillus in the vagina plays a key role in maintaining pH levels, and serves an active role in host defense mechanisms against pathologic infection. By secreting hydrogen peroxide and antibacterial/antifungal molecules, Lactobacillus species have been shown to inhibit growth of Candida and bacteria known to cause bacterial vaginosis. In addition, vaginosis has been associated with decreased colony counts of Lactobacillus, suggesting that lack of colonization may lead to increased susceptibility to infection.
Products containing Lactobacillus are available on the market. However, they are sold in the form of oral tablets which are meant to travel the gut before attempting to reach the vaginal target via a contaminated route.
Disclosed is a delivery device for use in colonizing the vagina with Lactobacillus in patients who test positive for or report symptoms of vaginitis. The device consists of an infused undergarment employing a sponge impregnated with Lactobacillus crispatus Freeze Dried Powder. The sponge, having channels to direct the powder, is held in place by a mesh fabric sewn into the groin portion of the garment, which allows the one way delivery of the powder. The infused undergarment may also be used to help maintain normal flora of the vagina in the absence of symptoms in a prophylactic manner to prevent future infection. The infused undergarment is sealed in an opaque aluminum foil package to prevent light and environment air from degrading the effectiveness of the infused undergarment.
An objective of the invention is to colonize the vagina with Lactobacillus crispatus bacterium using a wearable garment impregnated with Lactobacillus powder.
Another objective of the invention is to provide a probiotic undergarment to provide women with symptomatic relief of symptoms such as itching, burning, discharge, and odor.
Still another objective of the invention is to provide a probiotic undergarment that can result in resolution of bacterial and yeast infection without use of supplemental antibiotics or antifungals.
Another objective of the invention is to use the Lactobacillus garment for colonizing the vagina, alleviating symptoms of vaginitis, and treating vaginitis with and without traditional antibiotics/antifungal drugs.
An advantage of an infused undergarment of the invention is that the product provides a noninvasive treatment that administers the probiotic directly to the vulva and vagina. The infused undergarment does not require any insertion of tablets or gels. As the product is not inserted into the body, the patient will not need to have a prescription for the treatment. The active component is composed solely of Lactobacillus, making allergic reaction less likely.
Another advantage of the infused undergarment of the invention is that there is no latex in the device, avoiding the risk of latex allergy.
Yet still another advantage of an infused undergarment of the invention is that it allows direct contact with an affected area, which is more effective than taking an oral supplement that has to pass through the digestive system.
Other objectives and advantages of this invention will become apparent from the following description taken in conjunction with any accompanying drawings wherein are set forth, by way of illustration and example, certain embodiments of this invention. Any drawings contained herein constitute a part of this specification, include exemplary embodiments of the present invention, and illustrate various objects and features thereof.
While the present invention is susceptible of embodiments in various forms, there is shown in the drawings and will hereinafter be described a presently preferred embodiment with the understanding that the present disclosure is to be considered an exec exemplification of the invention and is not intended to limit the invention to the specific embodiments illustrated.
It is widely known that the presence of Lactobacillus in the vagina plays a key role in maintaining pH levels, and serves an active role in protecting against infection. Lactobacillus species have been shown to inhibit growth of Candida and bacteria known to cause bacterial vaginosis. In addition, vaginosis has been associated with decreased colony counts of Lactobacillus, suggesting that lack of colonization may lead to increased susceptibility to infection.
Referring to
Referring to
Referring to
A predetermined amount of Lactobacillus crispatus freeze dried powder is infused in the foam member 40. The Lactobacillus crispatus freeze dried powder is transferred through the groove 46 for dispersion through an elongated opening 35. The foam member 40 and receptacle 26 cause movement of the powder to be distributed along the grooves 46 and pass through the elongated opening 35 as a result of leg movement by the individual wearing the undergarment 10. The process allows woman to increase the colonization of Lactobacillus in addressing vaginal infections comprising the steps of:
Step 1: providing an undergarment 10 defined by a waist opening 12 at the top 14 of the undergarment, a left leg opening 16 at the bottom left 18 of the undergarment, a right leg opening 20 at the bottom right 22 of the undergarment, and a crotch portion 25 in between the left leg opening 16 and the right leg opening 20, and having a receptacle 26 formed integral or attached to said crotch section 25. The receptacle 26 having an elongated opening 35 extending a length between said left leg opening 16 and right leg opening 20.
Step 2: inserting a polyurethane foam member 40 having a predetermined amount of Lactobacillus crispatus Freeze Dried Powder infused in the foam member 40 into said receptacle 26.
Step 3: positioning said undergarment 10 on a woman's torso, wherein the individual wearing said undergarment 10 is treated with a release of said Lactobacillus crispatus freeze dried powder through said elongated opening 35 during leg movement for treatment of vaginal infections.
Step 4: repeating Steps 1-3 for ten consecutive days.
The foam member 40 with the Lactobacillus crispatus freeze dried powder operates in combination with grooves to expel the powder from the receptacle 26 through the opening 35. The leg movement of the individual allows movement of powder within the receptacle 26 and what could be described as a pump. The Lactobacillus crispatus freeze dried powder is flowable with good handling and packaging characteristics and formulate to retain functional attributes of the native biomolecule. In the preferred process stated above, the treatment is sold as a kit with ten individual packages of undergarments. The infused undergarment is stored in a sealed aluminum foil package. Sealing of the undergarment allows ease of use by simply opening of the package. The undergarments can be cleaned and reuse wherein the infused foam replacement member would be provided in sealed aluminum packages and inserted into a receptacle of undergarment.
The use of the word “a” or “an” when used conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more” or “at least one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”
The terms “comprise” (and any form of comprise, such as “comprises” and “comprising”), “have” (and any form of have, such as “has” and “having”), “include” (and any form of include, such as “includes” and “including”) and “contain” (and any form of contain, such as “contains” and “containing”) are open-ended linking verbs. As a result, a device that “comprises,” “has,” “includes” or “contains” one or more steps or elements, possesses those one or more steps or elements, but is not limited possessing only those one more elements. Likewise, a step of a method or an element of a device that “comprises,” “has,” “includes” or “contains” one or more features, possesses those one or more features, but is not limited to possessing only those one or more features. Furthermore, a device or structure that is configured in a certain way is configured in at least that way, but may also be configured in ways that are not listed.
It is to be understood that while a certain form of the invention is illustrated, it is not to be limited to the specific form or arrangement herein described and shown. It will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification and any drawings/figures included herein.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objectives and obtain the ends and advantages mentioned, as well as those inherent therein. The embodiments, methods, procedures, and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary, and are not intended as limitations on the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.
In accordance with 37 C.F.R. § 1.76, a claim, of priority is included in an Application Data Sheet filed concurrently herewith. Accordingly, the present invention claims priority based upon U.S. Provisional Patent Application No. 63/276,331, filed Nov. 5, 2021, entitled “INFUSED UNDERGARMENT”, the contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2102359 | Frieman | Dec 1937 | A |
2418907 | Schreiber | Apr 1947 | A |
2494292 | Frazer | Jan 1950 | A |
2595507 | Beck | May 1952 | A |
2719976 | Sussman | Oct 1955 | A |
3088462 | Muto | May 1963 | A |
3312981 | McGuire | Apr 1967 | A |
3490454 | Goldfarb | Jan 1970 | A |
3613686 | De Woskin | Oct 1971 | A |
3749095 | Toyama | Jul 1973 | A |
3875942 | Roberts | Apr 1975 | A |
3881490 | Whitehead | May 1975 | A |
4244059 | Pflaumer | Jan 1981 | A |
4421512 | Papajohn | Dec 1983 | A |
4731063 | Newkirk | Mar 1988 | A |
4790836 | Brecher | Dec 1988 | A |
4984304 | Brown | Jan 1991 | A |
5241710 | Lockhart | Sep 1993 | A |
5416929 | Braunstein | May 1995 | A |
5490847 | Correa | Feb 1996 | A |
6015816 | Kostyniak | Jan 2000 | A |
6041446 | Braunstein | Mar 2000 | A |
6409712 | Dutari | Jun 2002 | B1 |
7322966 | Deerin | Jan 2008 | B1 |
7601882 | Farbrot | Oct 2009 | B2 |
7752681 | Michel | Jul 2010 | B2 |
7858840 | Hisanaka | Dec 2010 | B2 |
8552249 | Akinsanya | Oct 2013 | B2 |
8575419 | Di Virgilio | Nov 2013 | B2 |
8935813 | O'Leary | Jan 2015 | B2 |
8993832 | Kuroda | Mar 2015 | B2 |
9003571 | Lewis-Williams | Apr 2015 | B1 |
9173782 | Takken | Nov 2015 | B2 |
9370451 | Hardy | Jun 2016 | B2 |
10420854 | Raver | Sep 2019 | B2 |
10765564 | Lee | Sep 2020 | B2 |
11298278 | Font Caselles | Apr 2022 | B2 |
11364156 | Zhao | Jun 2022 | B2 |
11850820 | Liu | Dec 2023 | B2 |
20040064120 | Berba | Apr 2004 | A1 |
20040122386 | Mocadlo | Jun 2004 | A1 |
20040122396 | Maldonado | Jun 2004 | A1 |
20060101558 | Coleman | May 2006 | A1 |
20070135009 | Liao | Jun 2007 | A1 |
20070287981 | Roe | Dec 2007 | A1 |
20080096001 | Emden | Apr 2008 | A1 |
20080109945 | Xia | May 2008 | A1 |
20090118574 | Stephenson | May 2009 | A1 |
20100152687 | Carlozzi | Jun 2010 | A1 |
20100249736 | Png | Sep 2010 | A1 |
20110023216 | O'Leary | Feb 2011 | A1 |
20120255103 | Evenstad | Oct 2012 | A1 |
20130108599 | Comeaux | May 2013 | A1 |
20130158635 | Federico | Jun 2013 | A1 |
20130281945 | Gallo | Oct 2013 | A1 |
20140295134 | Wood | Oct 2014 | A1 |
20140316363 | You | Oct 2014 | A1 |
20140358092 | Koumans | Dec 2014 | A1 |
20140378936 | Coates | Dec 2014 | A1 |
20150038040 | Gabbay | Feb 2015 | A1 |
20150133017 | Liao | May 2015 | A1 |
20150328060 | Bagger-Sjöbäck | Nov 2015 | A1 |
20150328061 | Bagger-Sjöbäck | Nov 2015 | A1 |
20150354101 | Liao | Dec 2015 | A1 |
20160030249 | Caneppele | Feb 2016 | A1 |
20160338881 | Hyppolite | Nov 2016 | A1 |
20170258650 | Rosati | Sep 2017 | A1 |
20170333260 | Garner | Nov 2017 | A1 |
20180132541 | Wittstadt | May 2018 | A1 |
20180318148 | Joshi | Nov 2018 | A1 |
20190070229 | Choi | Mar 2019 | A1 |
20190082748 | Mazourik | Mar 2019 | A1 |
20190116888 | White | Apr 2019 | A1 |
20190352445 | Zhao | Nov 2019 | A1 |
20190380886 | Hammond | Dec 2019 | A1 |
20200000155 | Etienne | Jan 2020 | A1 |
20200008986 | Hopkins | Jan 2020 | A1 |
20200063077 | Nolan | Feb 2020 | A1 |
20200068958 | Yabarafundi | Mar 2020 | A1 |
20200171107 | Parks | Jun 2020 | A1 |
20210016243 | Yonce | Jan 2021 | A1 |
20210030605 | Kajanthan | Feb 2021 | A1 |
20210146000 | Dagger | May 2021 | A1 |
20210298296 | Fayed | Sep 2021 | A1 |
20210338486 | Dagger | Nov 2021 | A1 |
20210338749 | Finlayson | Nov 2021 | A1 |
20210352970 | Monaco | Nov 2021 | A1 |
20220249301 | Wirsig | Aug 2022 | A1 |
20220378624 | Agud | Dec 2022 | A1 |
20220408848 | Krupa | Dec 2022 | A1 |
20220408850 | Laurin | Dec 2022 | A1 |
20230050850 | Miller | Feb 2023 | A1 |
20230059401 | Mellos | Feb 2023 | A1 |
20230081210 | Gaffney | Mar 2023 | A1 |
20230149481 | Finlayson | May 2023 | A1 |
20230228011 | Martin | Jul 2023 | A1 |
Number | Date | Country | |
---|---|---|---|
20230141346 A1 | May 2023 | US |
Number | Date | Country | |
---|---|---|---|
63276331 | Nov 2021 | US |